Abstract
Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide κ-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 696-699 |
| Number of pages | 4 |
| Journal | Bulletin of Experimental Biology and Medicine |
| Volume | 145 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 19 Nov 2008 |
Fingerprint
Keywords
- Chronic treatment with opioid receptor agonists
- Ischemia
- Myocardium
- Reperfusion
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists. / Lishmanov, Yu B.; Stakheev, D. L.; Krylatov, A. V.; Naryzhnaya, N. V.; Maslov, L. N.; Ovchinnikov, M. V.; Kolar, F.
In: Bulletin of Experimental Biology and Medicine, Vol. 145, No. 6, 19.11.2008, p. 696-699.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists
AU - Lishmanov, Yu B.
AU - Stakheev, D. L.
AU - Krylatov, A. V.
AU - Naryzhnaya, N. V.
AU - Maslov, L. N.
AU - Ovchinnikov, M. V.
AU - Kolar, F.
PY - 2008/11/19
Y1 - 2008/11/19
N2 - Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide κ-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.
AB - Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide κ-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.
KW - Chronic treatment with opioid receptor agonists
KW - Ischemia
KW - Myocardium
KW - Reperfusion
UR - http://www.scopus.com/inward/record.url?scp=56049095550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56049095550&partnerID=8YFLogxK
U2 - 10.1007/s10517-008-0172-9
DO - 10.1007/s10517-008-0172-9
M3 - Article
C2 - 19110553
AN - SCOPUS:56049095550
VL - 145
SP - 696
EP - 699
JO - Bulletin of Experimental Biology and Medicine
JF - Bulletin of Experimental Biology and Medicine
SN - 0007-4888
IS - 6
ER -